SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
HOOKIPA Pharma Inc. (HOOK) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+167.9%).
- Analyst consensus target $3.00 (+167.9% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — HOOK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.32
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.47
Book Value / Share$0.00
Revenue / Share$3.50
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$3.00 (+167.9%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-139.54 |
$0.00 |
$-12.72M |
- |
| 2018 |
$-177.57 |
$7.63M |
$-16.24M |
-212.8% |
| 2019 |
$-24.10 |
$11.94M |
$-43.04M |
-360.4% |
| 2020 |
$-16.93 |
$19.58M |
$-44.08M |
-225.1% |
| 2021 |
$-23.04 |
$18.45M |
$-75.67M |
-410.2% |
| 2022 |
$-9.91 |
$14.25M |
$-64.92M |
-455.6% |
| 2023 |
$-8.63 |
$20.13M |
$-81.58M |
-405.3% |
| 2024 |
$-3.47 |
$43.95M |
$-43.5M |
-99% |
